Affiliation:
1. Princess Margaret Cancer Centre University Health Network Toronto Ontario Canada
2. Stanford Cancer Institute Stanford University Stanford California USA
Abstract
In this issue, Rovsing et al. employ unbiased genome‐wide CRISPR screening and functional cellular assays to investigate the cellular response to vincristine, an important component of the front‐line DLBCL treatment R‐CHOP. Their findings reveal intriguing targets and mechanisms that hold promise for enhancing DLBCL treatment and provide a foundation for the development of future drug regimens. This research prompts further exploration of the translational potential to advance more effective and individualized approaches in the clinical management of DLBCL.Commentary on: Rovsing et al. Resistance to vincristine in DLBCL by disruption of p53‐induced cell cycle arrest and apoptosis mediated by KIF18B and USP28. Br J Haematol 2023;202:825–839.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献